Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Announces Phosphospecific Antibodies Production - Cellular phosphorylation is a reversible, covalent modification of a protein or lipid that results in the modification of the activity of the phosphorylated molecule by inducing small conformational changes within the molecule.1-2 - AnaSpec.com
AnaSpec Announces Phosphospecific Antibodies Production

 

PRZOOM - /newswire/ - Fremont, CA, United States, 2012/08/06 - Cellular phosphorylation is a reversible, covalent modification of a protein or lipid that results in the modification of the activity of the phosphorylated molecule by inducing small conformational changes within the molecule.1-2 - AnaSpec.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Catalyzed by protein kinases, phosphate groups can be added via the transfer of the terminal phosphate from a phosphate donor, e.g. ATP to an amino acid residue, such as serine, threonine or tyrosine (Figure 1). The functions of phosphorylation, the most prevalent of post-translational modifications, include the alteration of the activity of a substrate, its subcellular localization, binding properties with other proteins.1-2 To better understand phosphorylation and its functional role, the generation and use of phosphospecific antibodies is crucial.

For raising antibodies against phosphopeptides there are 3 critical factors for success: (1) the stability of the phosphorylation, (2) the purity of the peptide and (3) post-development purification of the phosphospecific antibody. With documented experience in meeting all three factors, AnaSpec, EGT Group is a proven source for world-class phosphospecific antibody production.

With full manufacturing facilities located in Fremont, CA, AnaSpec (anaspec.com) is able to maintain ISO9001:2008 manufacturing processes and robust quality validation. Our peptide chemists routinely synthesize sequences containing single and multiple phosphoamino acids using technologies that are fine-tuned to produce high-yield, ultra-pure phosphopeptides. Antibodies generated are then substantiated to be phosphospecific.
AnaSpec offers both polyclonal and monoclonal antibody production services for the generation of phospho and non-phosphospecific antibodies. For polyclonal antibodies, researchers have a choice between two immunization protocols - the Speedy 28-day protocol (an example of results is shown in Figure 2) and the 70-day standard protocol. As a trusted provider to the global research community, we are experienced in fulfilling the most stringent demands for optimizing project success. As well, AnaSpec carries a wide selection of phosphospecific catalog antibodies such as the Anti-p53’s and Anti-TAU’s. Phosphospecific antibodies that are zebrafish reactive are also available.

References:
1. Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th edition. New York: W H Freeman; 2002. Section 10.4, Covalent Modification Is a Means of Regulating Enzyme Activity.
2. Cohen, P. Proc R Soc Lond 234, 115 (1998). doi: 10.1098/rspb.1988.0040.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Announces Phosphospecific Antibodies Production

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen to Present 12 Abstracts At the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress
Imec Announces elPrep5 - the Newest Version of its Software Platform for DNA Analysis
Ipsen Showcases Commitment to Patient-centric Advances in Oncology with Record Number of Abstracts to be Presented At ESMO 2020 Virtual Congress
Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease Announced
Ipsen to Present New Insights At ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen to Present Results from MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP) At ASBMR 2020 Annual Meeting
DSM Ignites New Strategic Initiative to Transform Global Animal Nutrition and Health
Jamjoom Pharmaceuticals Earns Acclaim from Frost & Sullivan for its Dominance in the KSA Pharma Market
DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  RightITnow, Inc.

Visit  Limelon Advertising, Co.

Visit  BizJobs.com







 
  ©2020 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today